Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
US:NASDAQ Investor Relations:
ir.redhillbio.com/investor-relations
Company Research
Source: PR Newswire
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.LAS VEGAS, April 8, 2024 /PRNewswire/ -- DelveInsight's Giant-Cell Arteritis Market Insights report includes a comprehensive understanding of current treatment practices, giant-cell arteritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].Key Takeaways from the Giant-Cell Arteritis Market ReportAccording to DelveInsight's analysis, the market size for giant-cell arteritis reached USD 960 million in 2023 across the 7MM.In the 7MM, the United States accounted for the highest market size, with nearly 65% of the market share of the giant-cell arteritis market as compared to EU
Show less
Read more
Impact Snapshot
Event Time:
RDHL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDHL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDHL alerts
High impacting Redhill Biopharma Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
RDHL
News
- RedHill Biopharma Ltd. (NASDAQ: RDHL) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study [Yahoo! Finance]Yahoo! Finance
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyPR Newswire
- RedHill Biopharma Ltd. (NASDAQ: RDHL) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022) [Yahoo! Finance]Yahoo! Finance
RDHL
Sec Filings
- 4/24/24 - Form 6-K
- 4/23/24 - Form EFFECT
- 4/18/24 - Form POS
- RDHL's page on the SEC website